| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK11A |
| Uniprot No | Q9UQ88 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-783aa |
| 氨基酸序列 | MGDEKDSWKV KTLDEILQEK KRRKEQEEKA EIKRLKNSDD RDSKRDSLEE GELRDHCMEI TIRNSPYRRE DSMEDRGEED DSLAIKPPQQ MSRKEKVHHR KDEKRKEKWK HARVKEREHE RRKRHREEQD KARREWERQK RREMAREHSR RERDRLEQLE RKRERERKMR EQQKEQREQK ERERRAEERR KEREARREVS AHHRTMREDY SDKVKASHWS RSPPRPPRER FELGDGRKPG EARPAPAQKP AQLKEEKMEE RDLLSDLQDI SDSERKTSSA ESSSAESGSG SEEEEEEEEE EEEEGSTSEE SEEEEEEEEE EEEETGSNSE EASEQSAEEV SEEEMSEDEE RENENHLLVV PESRFDRDSG ESEEAEEEVG EGTPQSSALT EGDYVPDSPA LLPIELKQEL PKYLPALQGC RSVEEFQCLN RIEEGTYGVV YRAKDKKTDE IVALKRLKME KEKEGFPITS LREINTILKA QHPNIVTVRE IVVGSNMDKI YIVMNYVEHD LKSLMETMKQ PFLPGEVKTL MIQLLRGVKH LHDNWILHRD LKTSNLLLSH AGILKVGDFG LAREYGSPLK AYTPVVVTQW YRAPELLLGA KEYSTAVDMW SVGCIFGELL TQKPLFPGNS EIDQINKVFK ELGTPSEKIW PGYSELPVVK KMTFSEHPYN NLRKRFGALL SDQGFDLMNK FLTYFPGRRI SAEDGLKHEY FRETPLPIDP SMFPTWPAKS EQQRVKRGTS PRPPEGGLGY SQLGDDDLKE TGFHLTTTNQ GASAAGPGFS LKF |
| 预测分子量 | 91,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDK11A重组蛋白的参考文献示例(内容基于领域内常见研究方向，部分为假设性概括)：
1. **文献名称**：*Expression and Functional Characterization of Recombinant CDK11A in Cancer Cell Models*
**作者**：Smith J, et al.
**摘要**：该研究描述了在大肠杆菌系统中重组表达CDK11A蛋白的优化方法，并通过体外激酶实验验证其磷酸化底物的活性。进一步利用该重组蛋白探究了CDK11A在乳腺癌细胞周期调控中的作用。
2. **文献名称**：*Structural Insights into CDK11A-Ligand Interactions Using Cryo-EM*
**作者**：Chen L, et al.
**摘要**：通过冷冻电镜技术解析了重组CDK11A蛋白与其小分子抑制剂的复合物结构，揭示了结合位点的关键氨基酸残基，为靶向CDK11A的抗癌药物设计提供了结构基础。
3. **文献名称**：*CDK11A Regulates Pre-mRNA Splicing via Phosphorylation of Splicing Factors*
**作者**：Wang Y, et al.
**摘要**：研究团队利用纯化的重组CDK11A蛋白进行体外磷酸化实验，证明其直接磷酸化剪接因子SF3B1.并阐明了该修饰在RNA剪接异常和白血病发生中的潜在机制。
4. **文献名称**：*Development of a High-Throughput Screening Assay for CDK11A Inhibitors Using Recombinant Protein*
**作者**：Garcia R, et al.
**摘要**：基于重组CDK11A蛋白建立了一种高通量激酶活性检测体系，筛选了化合物库并鉴定出多个具有选择性抑制活性的先导化合物，为肿瘤治疗提供新策略。
---
注：以上文献为示例性内容，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。建议结合具体研究方向补充关键词(如“CDK11A/p110 purification”、“kinase assay”、“drug discovery”)进行精准查询。
**Background of CDK11A Recombinant Protein**
CDK11A (Cyclin-Dependent Kinase 11A), also known as CDC2L3 or PITSLRE, is a member of the cyclin-dependent kinase (CDK) family, which plays critical roles in cell cycle regulation, transcription, and RNA splicing. It is encoded by the *CDK11* gene located on human chromosome 1p36.3. CDK11A interacts with cyclin L to form a functional kinase complex, regulating key cellular processes such as mitotic progression, apoptosis, and DNA damage response. Unlike other CDKs, CDK11A exists in multiple isoforms generated through alternative splicing, contributing to its functional diversity.
Recombinant CDK11A protein is produced using heterologous expression systems (e.g., *E. coli* or mammalian cells*) to ensure high purity and activity. This engineered protein retains the kinase domain and catalytic activity, enabling researchers to study its biochemical properties, substrate interactions, and regulatory mechanisms *in vitro*. CDK11A is implicated in cancer biology due to its dysregulation in malignancies like breast cancer, leukemia, and neuroblastoma, where it influences tumor cell proliferation and survival.
The recombinant protein serves as a vital tool for structural studies, inhibitor screening, and functional assays aimed at understanding CDK11A's role in disease pathways. It also supports drug discovery efforts targeting CDK11A, which is emerging as a potential therapeutic target for cancers resistant to conventional therapies.
×
